The Patent Finder
HE

Henry Company LLC

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

133 patents currently held

55 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.

The next US patent term in the Henry Company LLC portfolio ends in Feb 2027, and more of its terms end in 2036 (18) than in any other year. from the record

Of the 55 now held by other companies, 20 name Kyocera Corporation as their current owner, and 35 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Feb 2027
Next term end
100
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations US 9,206,481
The most cited patent in this portfolio, cited by 120 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2029.
Ends Apr 2029 · High confidence
Also notable
Apparatus and Method for Controlled Depth of Injection into Myocardial Tissue US 8,801,665
Cited by 47 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Ends Apr 2029 · High confidence
Also notable
Low-Dust Products Using a Wax Emulsion US 10,801,217
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Ends Sep 2036 · High confidence

Formerly held, still cited

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 20 to 25, 2026 · next Dec 20
  • 4 fees due Jan 7 to 30, 2027 · next Jan 7
  • 2 fees due Feb 6 to 20, 2027 · next Feb 6
  • 2 fees due Mar 5 to 17, 2027 · next Mar 5
  • 3 fees due Apr 8 to 24, 2027 · next Apr 8
  • 1 fee due May 17, 2027
    The maintenance fee for Compositions Containing Nucleosides and Manganese and Their Uses (US 9,186,406) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
  • 3 fees due Jun 8 to 24, 2027 · next Jun 8
  • 2 fees due Jul 9 to 12, 2027 · next Jul 9
  • 2 fees due Aug 23 to 27, 2027 · next Aug 23
  • 3 fees due Oct 23 to 30, 2027 · next Oct 23
  • 1 fee due Nov 10, 2027
    The maintenance fee for Isolation and Detection of Cancer Cells (US 9,335,327) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 5 of the patents on this record were granted since Aug 24, 2026
  • 6 terms have ended since Aug 24, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,988,971Human Monoclonal Antibodies Against Hendra and Nipah Viruses
In force
 · High confidence
In forceHigh confidence
US 7,893,094Amphiphilic Pyridinium Compounds, Method of Making and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 7,875,017Cardiac Repair, Resizing and Reshaping Using the Venous System of the Heart
In force
 · High confidence
In forceHigh confidence
US 8,945,573Targeted Identification of Immunogenic Peptides
In force
 · Medium confidence
In forceMedium confidence
US 8,865,171Soluble Forms of Hendra and Nipah Virus G Glycoprotein
In force
 · High confidence
In forceHigh confidence
US 7,880,465Method and Apparatus for Contrast Inflow Dynamic MR Angiography
In force (reinstated)
 · High confidence
In force (reinstated)High confidence
US 8,801,665Apparatus and Method for Controlled Depth of Injection into Myocardial Tissue
In force (reinstated)
 · High confidence
In force (reinstated)High confidence
US 9,399,082Electrospun Dextran Fibers and Devices Formed Therefrom
In force
 · High confidence
In forceHigh confidence
US 10,046,081Electrospun Dextran Fibers and Devices Formed Therefrom
In force
 · High confidence
In forceHigh confidence
US 12,171,888Electrospun Dextran Fibers and Devices Formed Therefrom
In force
 · High confidence
In forceHigh confidence
10 of 133 patents shown.
Pro members see all 133.
Pro members: see all 133 patents
Also on record, not counted in the 133: 55 patents in force now held by others · 70 patents ended · 74 applications pending · 99 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited